Lessons From a Cardiovascular Outcome Trial With Liraglutide in Type 2 Diabetes

Journal of Diabetes Investigation - Australia
doi 10.1111/jdi.12607
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An Analysis From a Diabetes Outcome Progression Trial (ADOPT)

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2008English

Cardiovascular Outcome Trials of Diabetes Drugs: Lessons Learned

Journal of Clinical Investigation
Medicine
2018English

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Independent of LDL Cholesterol and Statin Use: Results of the Leader Trial

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2018English

Potential of Liraglutide in the Treatment of Patients With Type 2 Diabetes

Vascular Health and Risk Management
2009English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Risk of Major Cardiovascular Events in Patients With Type 2 Diabetes With and Without Prior Cardiovascular Events: Results From the Leader Trial

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?

Journal of Clinical Medicine Research
2014English

Design and Baseline Characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

Diabetes and Vascular Disease Research
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2015English

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy